All In Biotech

Drug Trial Radar · NCT04484623

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 302 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

302

Actual

Start

Oct 1, 2020

Primary completion

Jan 29, 2024

Study completion Jun 25, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

Conditions

  • Multiple Myeloma

Interventions

  • Belantamab mafodotinDrug

    Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.

  • PomalidomideDrug

    Immunomodulatory drug (IMiD) will be administered.

  • DexamethasoneDrug

    Synthetic glucocorticoid with anti-tumor activity will be administered.

  • BortezomibDrug

    Proteasome Inhibitor will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 174 weeks

Locations

122 sites in 18 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Garran, Australian Capital Territory, Australia

  • GSK Investigational Site

    Darlinghurst, New South Wales, Australia

  • GSK Investigational Site

    Gosford NSW, New South Wales, Australia

  • GSK Investigational Site

    Port Macquarie, New South Wales, Australia

  • GSK Investigational Site

    Benowa, Queensland, Australia

  • GSK Investigational Site

    South Brisbane, Queensland, Australia

  • GSK Investigational Site

    Adelaide, South Australia, Australia

  • GSK Investigational Site

    Fitzroy, Victoria, Australia

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Malvern, Victoria, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Curitiba, Brazil

  • GSK Investigational Site

    Joinville, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Changchun, China

  • GSK Investigational Site

    Changsha, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Hangzhou, China

  • GSK Investigational Site

    Jiangsu, China

  • GSK Investigational Site

    Nanchang, China

  • GSK Investigational Site

    Shenyang, China

  • GSK Investigational Site

    Shenzhen, China

  • GSK Investigational Site

    Tianjin, China

  • GSK Investigational Site

    Wuhan, China

  • GSK Investigational Site

    Brno, Czechia

  • GSK Investigational Site

    Hradec Králové, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Toulouse, France

  • GSK Investigational Site

    Vanduvre-lEs-Nancy, France

  • GSK Investigational Site

    Mainz, Germany

  • GSK Investigational Site

    Tübingen, Germany

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.